Navigation Links
Australian Biotech Ceridia Pty Ltd Completes Successful Human Clinical Trial
Date:7/26/2011

ADELAIDE, Australia, July 26, 2011 /PRNewswire/ -- Ceridia Pty Ltd., a biotechnology company focused on reformulating and developing therapeutic drugs, announce the successful completion of Phase 1 Proof-of-Concept study of its novel LipoCeramic ibuprofen formulation, CER006.  CER006 was designed to be a model formulation to establish safety and tolerability of Ceridia's LipoCeramic reformulation technology but also to attain pharmacokinetic information in humans.

Trial demonstrates that the technology is safe and well tolerated. Study also suggests fast and improved delivery of ibuprofen when comparing with branded market leader.

Based on the safety and pharmacokinetics data from this 4-arm blinded study, Ceridia plans to commence a number of bio-equivalence and bioavailability trials which will include anti-inflammatory, anti-infective and oncology drugs.

"We are very pleased to demonstrate that Ceridia's LipoCeramic platform technology is safe and well tolerated in humans.  It is a clinical validation of more than 10 years of research and development," said Dr Gregor Rozenberg, Ph.D., CEO, Ceridia. "We are now poised to initiate a number of Phase 2 studies with the aim of reformulating and improving the clinical profiles of several therapeutic drugs.  Commercialisation can now be accelerated."

Ceridia Pty Ltd is supported by ITEK, the intellectual property commercialisation arm of UniSA and has entered into collaborations with Pharma and Biotech using its innovative reformulation technology to improve existing and novel drugs. The company is seeking additional investment and partnerships.

Reformulating approved drugs enables reprofiling or repurposing of therapeutic agents. This in turn provides new commercial opportunities in an abbreviated regulatory environment. This reduces development times significantly and produces better drugs quicker and cheaper.

Ceridia

Ceridia is a privately owned spin-out company of the University of South Australia.  Ceridia is commercializing a novel method of reformulating oil-soluble compounds.  A silica-lipid nano-encapsulation platform technology has been developed and protected by patents worldwide.  This technology enables the pharmaceutical and biotechnology industry to improve efficacy, bio-availability and stability of drugs and help reduce their time to market.  The technology is clinically proven to be completely safe, uses no synthetic, toxic or corrosive solvents. The manufacturing process is straightforward and can be quickly transferred into most API manufacturing sites and requires no additional capital expenditure.  Human clinical trials indicate improved clinical profile and quicker drug uptake.

Contact:
Gregor Rozenberg, CEO
Email: gregor@ceridia.com.au
Website: www.ceridia.com.au


'/>"/>
SOURCE Ceridia Pty Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Australian Center Readies Brain Research Program for Addition of Elekta MEG System
2. Cephalon Launches Recommended Takeover Bid For Australian Biopharmaceutical Company, ChemGenex Pharmaceuticals Limited
3. OrthoAccel Technologies, Inc. and AB Orthodontics Announce Partnership and Australian Product Introduction
4. New Australian Drug Holds Hope of Major Breakthrough in Treating Terminal Blood Cancers
5. New Australian Technology: Detecting Breast Cancer With Hair
6. Kibow Biotech Obtains Australian, Chinese and Indian Patents Protecting the Composition and Basic Technology Behind Its Oral Probiotic Formulation for Chronic Kidney Failure
7. Top 5 Ways to Get Insider Track on Healthcare, Pharma & Biotech Discoveries & Latest News
8. Aeras and China National Biotech Group Sign Memorandum of Understanding for TB Vaccine R&D Collaboration
9. 2011 Prix Galien USA Final Candidates Announced: Competing for Best Biotechnology Product and Best Pharmaceutical Agent
10. Lilly Announces New Investment to Further Boost Its Biotechnology Capabilities
11. Goodwin Biotechnology Announces a Collaboration With Alethia Biotherapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/15/2017)... Enterin Inc., a privately-held CNS pharmaceutical company based in ... Parkinson,s disease (PD), has enrolled the first patient in the ... multicenter study involving patients with PD and taking place at ... 9-to-12-month period. The first stage is open label and involves ... include Denver , Boca Raton ...
(Date:5/11/2017)... TORONTO , May 11, 2017  Thornhill ... ) has been awarded an $8,049,024 USD five-year, ... Defense through the Canadian Commercial Corporation (CCC) ( ... Field Anesthesia Systems to administer general anesthesia to ... environment.  "The US Marine Corps have ...
(Date:5/10/2017)... 2017 Global Health Intelligence (GHI), the ... , published its 2017 ranking of the Best-Equipped ... extensive data analysis from GHI,s hospitals database for Latin ... the region. The GHI database covers 86% of the hospitals ... 130 data points for each institution in key areas such ...
Breaking Medicine Technology:
(Date:5/22/2017)... ... May 22, 2017 , ... Faithfully following pop culture, ... squatted, stretched, jumped, toned and shaped through fitness programs. It carries on to skin ... finished off with an irresistible, radiant smile. CDA has found that just ...
(Date:5/21/2017)... ... May 19, 2017 , ... ... announce the appointment of James (Jim) Vertino as Chief Information Officer (CIO). He ... transformational leader who drives innovation and business performance. He defines strategic roadmaps by ...
(Date:5/21/2017)... ... May 21, 2017 , ... ... together a cross-disciplinary group of scholars, policymakers, and activists wanting to address equity ... Equity is the third book from a recent series of from this ...
(Date:5/21/2017)... ... May 21, 2017 , ... Dental visits are ... months since you've seen a dentist, it's time for a dental checkup. The ... once per year. , Dental checkups are a relatively easy procedure that involves ...
(Date:5/19/2017)... Kansas City, Mo (PRWEB) , ... May 19, 2017 , ... ... on Saturday, May 20, his name will already appear on two major research studies ... Busch has been working with Dr. Matt Daggett, KCU alumnus and an orthopedic surgeon, ...
Breaking Medicine News(10 mins):